EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 31 / No 8-9 (Août–Septembre 2015) Med Sci (Paris), 31 8-9 (2015) 797-803 References
Free Access
Issue
Med Sci (Paris)
Volume 31, Number 8-9, Août–Septembre 2015
Page(s) 797 - 803
Section Forum
DOI https://doi.org/10.1051/medsci/20153108020
Published online 04 September 2015
  1. Collins FS. The langage of life: DNA and the revolution of personalized medicine. New York : Harper Perennial, 2011. [Google Scholar]
  2. Cullis P. The personalized medicine revolution. How diagnosing and treating disease are about to change forever. Vancouver : Greystone Books, 2015. [Google Scholar]
  3. Guchet X. Les promesses de la médecine personnalisée. In: Audétat M, Barazzetti G, Dorthe G, Joseph C, et al., eds. Sciences et technologies émergentes : pourquoi tant de promesses ? Paris : Hermann, 2015 (sous presse). [Google Scholar]
  4. Marino P. Tests diagnostiques et thérapies ciblées en cancérologie. Enjeux économiques. Med Sci (Paris) 2012; 28 (hors série n° 1) : 19–22. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Paci A (sous la direction de). Médecine personnalisée et cancer. Organiser et financer l’accès à l’innovation. Villejuif : Presses de l’Institut Gustave Roussy, 2013. [Google Scholar]
  6. Seror V. Perspective économique sur les traitements ciblés. Med Sci (Paris) 2014; 30 (hors série n° 2) : 32–35. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. New Biotechnol 2012 ; 29 : 757–768. [CrossRef] [Google Scholar]
  8. Feldman EA. The genetic information nondiscrimination act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med 2011 ; 27 : 743–746. [CrossRef] [Google Scholar]
  9. Weigman K. Racial medicine: here to stay? EMBO Rep 2006 ; 7 : 246–249. [CrossRef] [PubMed] [Google Scholar]
  10. Kahn J. Race in a bottle: the story of BiDil and racialized medicine in a post-genomic age. New York : Columbia University Press, 2013. [Google Scholar]
  11. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Hum Genet 2011 ; 12 : 217–244. [Google Scholar]
  12. De Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2013 ; 467 : 543–549. [CrossRef] [Google Scholar]
  13. Baker M. Big biology: the ome’s puzzle. Nature 2013 ; 494 : 416–419. [CrossRef] [PubMed] [Google Scholar]
  14. National research council. Toward precision medicine. Building a knowledge. Network for biomedical research and a new taxonomy of disease. Washington : National Academies Press, 2011. [Google Scholar]
  15. Accenture. The pursuit of high performance through research and development. Understanding pharmaceutical research and development cost drivers. Accenture, 2007. Available at: http://www.accenture.com/Microsites/rdtransformation/Documents/PDFs/Accenture_In_Pursuit_of_High_Performance.pdf. [Google Scholar]
  16. Langreth R, Waldholz M. New era of personalized medicine. Targeting drugs for each unique genetic profile. Oncologist 1999 ; 4 : 426–427. [PubMed] [Google Scholar]
  17. Morgan M. News paradigms in industry: the single nucleotide polymorphism consortium. In: Esanu JM, Uhlir PF, eds. The role of scientific and technical data and information in the public domain. Proceedings of a Symposium, chapter 28. Washington : National Academy of Sciences, 2003. [Google Scholar]
  18. Rajan KS Biocapital. The construction of postgenomic life. Duham and London : Duke University Press, 2006. [Google Scholar]
  19. Food and Drugs Administration. Paving the way for personalized medicine: FDA’s role in a new era of medical product development. FDA, 2013. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf. [Google Scholar]
  20. Ng PC, Murray SS, Levy S, Venter JC An agenda for personalized medicine. Nature 2009 ; 461 : 724–726. [CrossRef] [PubMed] [Google Scholar]
  21. NIH. Precision medicine initiative. Available at: http://www.nih.gov/precisionmedicine/ [Google Scholar]
  22. Topol EJ. Individualized medicine from prewomb to the tomb. Cell 2014 ; 157 : 241–253. [CrossRef] [PubMed] [Google Scholar]
  23. Gaudillière JP. Inventer la biomédicine. La France, l’Amérique et la production des savoirs du vivant (1945–1965). Paris : La Découverte, 2002. [Google Scholar]
  24. Mamo L, Clarke AE, Fosket JR, et al. (eds). Biomedicalization. Technoscience, health, and illness in the US. Durham : Duke University Press, 2010 : 512 p. [Google Scholar]
  25. Cambrosio A, Keating P. Qu’est-ce que la biomédecine ? Repères socio-historiques. Med Sci (Paris) 2013 ; 12 : 1280–1287. [Google Scholar]
  26. Foucault M. Naissance de la clinique. Une archéologie du regard médical. Paris : PUF, 1963. [Google Scholar]
  27. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012 ; 148 : 1293–1307. [CrossRef] [PubMed] [Google Scholar]
  28. Nelson N, Keating P, Cambrosio A. On being actionable: clinical sequencing and the emerging contours of a regime of genomic in medicine in oncology. New Genet Soc 2013 ; 32 : 405–428. [CrossRef] [Google Scholar]
  29. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013 ; 339 : 1546–1558. [Google Scholar]
  30. Arnedos M, Viehl P, Soria JC, André F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014 ; 232 : 274–282. [CrossRef] [PubMed] [Google Scholar]
  31. Callon M. Les incertitudes scientifiques et techniques constituent-elles une source possible de renouvellement de la vie démocratique ? Papiers de Recherche du CSI. Paris : Centre de Sociologie de l’Innovation, Mines ParisTech, 2012. [Google Scholar]
  32. Majewski IJ, Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011 ; 17 : 304–312. [CrossRef] [PubMed] [Google Scholar]
  33. Guchet X. La médecine personnalisée. Une approche philosophique. Paris : Hermann, 2015 (sous presse). [Google Scholar]
  34. Tursz T, André F, Lazar V, et al. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011 ; 8 : 177–183. [CrossRef] [PubMed] [Google Scholar]
  35. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014 ; 15 : 267–274. [CrossRef] [PubMed] [Google Scholar]
  36. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015 ; 33 : 975–977. [CrossRef] [PubMed] [Google Scholar]
  37. Bateman S. Médecine personnalisée. Un concept flou, des pratiques diversifiées. Med Sci (Paris) 2014 ; 2 : 8–13. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  38. Institute for Systems Biology. 100K Wellness Project. Available at: http://research.systemsbiology.net/100k/ [Google Scholar]
  39. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011 ; 8 : 184–187. [CrossRef] [PubMed] [Google Scholar]
  40. Hood L, Flores MA. Personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnol 2012 ; 29 : 613–622. [CrossRef] [Google Scholar]
  41. Pinell P. Naissance d’un fléau : histoire de la lutte contre le cancer en France (1890–1940). Paris : Métailié, 1992. [Google Scholar]
  42. Sfez L. La santé parfaite. Critique d’une nouvelle utopie. Paris : Seuil, 1995. [Google Scholar]
  43. Rose N. Personalized medicine: promises, problems and perils of a new paradigm for healthcare. Procedia Soc Behav Sci 2013 ; 77 : 341–352. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.